PDF herunterladen
Semin Liver Dis 2015; 35(03): 304-317
DOI: 10.1055/s-0035-1562949
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude

Christine Pocha
1   Hepatology, University Clinic for Visceral Surgery and Medicine, University of Berne, Berne, Switzerland
,
Philippe Kolly
1   Hepatology, University Clinic for Visceral Surgery and Medicine, University of Berne, Berne, Switzerland
2   Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
,
Jean-Francois Dufour
1   Hepatology, University Clinic for Visceral Surgery and Medicine, University of Berne, Berne, Switzerland
2   Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. September 2015 (online)

    Lizenzen und Reprints

Abstract

Hepatocellular carcinoma (HCC) is a cancer with globally rising incidence. Growing evidence supports associations between metabolic syndrome and diabetes as well as obesity and HCC arising in patients with nonalcoholic fatty liver disease (NAFLD). This constitutes a problem of alarming magnitude given the rising epidemic of these conditions. The role of diabetes seems to be particularly important when associated with obesity or cirrhosis. Excess hepatic iron may be another potential risk factor for the development of NAFLD-associated HCC. In the context of NAFLD, HCC frequently develops in a not-yet cirrhotic liver. As there are no surveillance programs for these patients, diagnosis often occurs at a tumor stage beyond curative options. Clinical, tumor, and patient characteristics in NAFLD-associated HCC differ from other etiologies. Older age and cardiovascular comorbidities may limit treatment options further. The outcome in patients with NAFLD-associated early HCC is excellent and therefore aggressive treatment should be pursued in appropriate patients. Population-based prevention to reduce the culprit—NAFLD—early recognition through targeted surveillance programs in risk-stratified patients and effective treatment of HCC associated with NAFLD are urgently needed. In this review, the authors summarize the epidemiology, risk factors, features, and prevention of NAFLD-associated HCC.

Keywords

hepatocellular cancer - insulin resistance - nonalcoholic fatty liver disease - obesity
 

  • References

  • 1 Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121 (1) 91-100
    CrossrefPubMedSuche in Google Scholar
  • 2 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8 (3) 521-533 , viii viii
    CrossrefPubMedSuche in Google Scholar
  • 3 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42 (1) 44-52
    CrossrefPubMedSuche in Google Scholar
  • 4 El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365 (12) 1118-1127
    CrossrefPubMedSuche in Google Scholar
  • 5 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2) 69-90
    CrossrefPubMedSuche in Google Scholar
  • 6 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27 (9) 1485-1491
    CrossrefPubMedSuche in Google Scholar
  • 7 Mittal S, Sada YH, El-Serag HB , et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13 (3) 594-601.e1
    CrossrefPubMedSuche in Google Scholar
  • 8 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51 (6) 1972-1978
    CrossrefPubMedSuche in Google Scholar
  • 9 Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26 (9) 2183-2191
    CrossrefPubMedSuche in Google Scholar
  • 10 Söderberg C, Stål P, Askling J , et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (2) 595-602
    CrossrefPubMedSuche in Google Scholar
  • 11 Arase Y, Kobayashi M, Suzuki F , et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012; 42 (3) 264-272
    CrossrefPubMedSuche in Google Scholar
  • 12 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
    CrossrefPubMedSuche in Google Scholar
  • 13 Ekstedt M, Franzén LE, Mathiesen UL , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (4) 865-873
    CrossrefPubMedSuche in Google Scholar
  • 14 Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44 (10) 1236-1243
    CrossrefPubMedSuche in Google Scholar
  • 15 Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49 (4) 608-612
    CrossrefPubMedSuche in Google Scholar
  • 16 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307 (5) 491-497
    CrossrefPubMedSuche in Google Scholar
  • 17 Wong VW, Wong GL, Tsang SW , et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009; 29 (4) 387-396
    CrossrefPubMedSuche in Google Scholar
  • 18 Paradis V, Zalinski S, Chelbi E , et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49 (3) 851-859
    CrossrefPubMedSuche in Google Scholar
  • 19 Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42 (2) 218-224
    PubMedSuche in Google Scholar
  • 20 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348 (17) 1625-1638
    CrossrefPubMedSuche in Google Scholar
  • 21 Møller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A (3) 344-350
    PubMedSuche in Google Scholar
  • 22 Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97 (7) 1005-1008
    PubMedSuche in Google Scholar
  • 23 Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612) 569-578
    CrossrefPubMedSuche in Google Scholar
  • 24 Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 2010; 31 (10) 1051-1063
    PubMedSuche in Google Scholar
  • 25 Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni Jr JF. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15 (1) 35-43
    CrossrefPubMedSuche in Google Scholar
  • 26 Schlesinger S, Aleksandrova K, Pischon T , et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013; 132 (3) 645-657
    CrossrefPubMedSuche in Google Scholar
  • 27 Ohki T, Tateishi R, Shiina S , et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009; 58 (6) 839-844
    CrossrefPubMedSuche in Google Scholar
  • 28 Fujiwara N, Nakagawa H, Kudo Y , et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63 (1) 131-140
    CrossrefPubMedSuche in Google Scholar
  • 29 Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002; 36 (1) 150-155
    CrossrefPubMedSuche in Google Scholar
  • 30 Berentzen TL, Gamborg M, Holst C, Sørensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol 2014; 60 (2) 325-330
    CrossrefPubMedSuche in Google Scholar
  • 31 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54 (2) 463-471
    CrossrefPubMedSuche in Google Scholar
  • 32 Dyson J, Jaques B, Chattopadyhay D , et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60 (1) 110-117
    CrossrefPubMedSuche in Google Scholar
  • 33 Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11 (1) 191-207 , x–xi x –xi
    CrossrefPubMedSuche in Google Scholar
  • 34 Chun YS, Huang M, Rink L, Von Mehren M. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study. World J Surg Oncol 2014; 12: 231
    CrossrefPubMedSuche in Google Scholar
  • 35 Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16 (12) 1436-1441
    CrossrefPubMedSuche in Google Scholar
  • 36 Wideroff L, Gridley G, Mellemkjaer L , et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89 (18) 1360-1365
    CrossrefPubMedSuche in Google Scholar
  • 37 Adami HO, Chow WH, Nyrén O , et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88 (20) 1472-1477
    CrossrefPubMedSuche in Google Scholar
  • 38 Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92 (13) 1096-1099
    CrossrefPubMedSuche in Google Scholar
  • 39 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126 (2) 460-468
    CrossrefPubMedSuche in Google Scholar
  • 40 El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4 (3) 369-380
    CrossrefPubMedSuche in Google Scholar
  • 41 Turati F, Talamini R, Pelucchi C , et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013; 108 (1) 222-228
    CrossrefPubMedSuche in Google Scholar
  • 42 Chen CL, Yang HI, Yang WS , et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135 (1) 111-121
    CrossrefPubMedSuche in Google Scholar
  • 43 Chen HF, Chen P, Li CY. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology 2010; 52 (1) 155-163
    CrossrefPubMedSuche in Google Scholar
  • 44 Bugianesi E, Leone N, Vanni E , et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 (1) 134-140
    CrossrefPubMedSuche in Google Scholar
  • 45 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54 (4) 533-539
    CrossrefPubMedSuche in Google Scholar
  • 46 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration?. Clin Res Hepatol Gastroenterol 2012; 36 (3) 202-208
    CrossrefPubMedSuche in Google Scholar
  • 47 Borena W, Strohmaier S, Lukanova A , et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012; 131 (1) 193-200
    CrossrefPubMedSuche in Google Scholar
  • 48 Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99 (2) 292-298
    CrossrefPubMedSuche in Google Scholar
  • 49 George DK, Goldwurm S, MacDonald GA , et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114 (2) 311-318
    CrossrefPubMedSuche in Google Scholar
  • 50 Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 1996; 16 (1) 13-30
    Thieme ConnectPubMedSuche in Google Scholar
  • 51 Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46 (4) 1291-1301
    CrossrefPubMedSuche in Google Scholar
  • 52 Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50 (2) 351-357
    CrossrefPubMedSuche in Google Scholar
  • 53 Valenti L, Fracanzani AL, Dongiovanni P , et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102 (6) 1251-1258
    CrossrefPubMedSuche in Google Scholar
  • 54 Nirei K, Matsuoka S, Nakamura H, Matsumura H, Moriyama M. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. Intern Med 2015; 54 (2) 107-117
    CrossrefPubMedSuche in Google Scholar
  • 55 Fujita N, Miyachi H, Tanaka H , et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009; 18 (2) 424-432
    CrossrefPubMedSuche in Google Scholar
  • 56 Sakurai K, Sohda T, Ueda S , et al. Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue. Hepatogastroenterology 2014; 61 (130) 426-430
    PubMedSuche in Google Scholar
  • 57 Younossi ZM, Gramlich T, Bacon BR , et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30 (4) 847-850
    CrossrefPubMedSuche in Google Scholar
  • 58 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 (6) 1356-1362
    CrossrefPubMedSuche in Google Scholar
  • 59 Greeve M, Ferrell L, Kim M , et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 1993; 17 (4) 593-598
    CrossrefPubMedSuche in Google Scholar
  • 60 Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24 (4) 813-815
    CrossrefPubMedSuche in Google Scholar
  • 61 Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11 (1) 74-80
    CrossrefPubMedSuche in Google Scholar
  • 62 Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29 (3) 664-669
    CrossrefPubMedSuche in Google Scholar
  • 63 Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32 (4 Pt 1): 689-692
    CrossrefPubMedSuche in Google Scholar
  • 64 Rafiq N, Bai C, Fang Y , et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7 (2) 234-238
    CrossrefPubMedSuche in Google Scholar
  • 65 Adams LA, Lymp JF, St Sauver J , et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (1) 113-121
    CrossrefPubMedSuche in Google Scholar
  • 66 Younossi ZM, Stepanova M, Rafiq N , et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (6) 1874-1882
    CrossrefPubMedSuche in Google Scholar
  • 67 Ertle J, Dechêne A, Sowa JP , et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128 (10) 2436-2443
    CrossrefPubMedSuche in Google Scholar
  • 68 Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24 (2) 248-254
    CrossrefPubMedSuche in Google Scholar
  • 69 Yasui K, Hashimoto E, Komorizono Y , et al; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9 (5) 428-433 , quiz e50
    CrossrefPubMedSuche in Google Scholar
  • 70 Lee SS, Jeong SH, Byoun YS , et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 2013; 13: 335
    CrossrefPubMedSuche in Google Scholar
  • 71 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36 (6) 1349-1354
    CrossrefPubMedSuche in Google Scholar
  • 72 Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011; 46 (10) 1230-1237
    CrossrefPubMedSuche in Google Scholar
  • 73 Hashimoto E, Yatsuji S, Tobari M , et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl. 19) 89-95
    CrossrefPubMedSuche in Google Scholar
  • 74 Kawada N, Imanaka K, Kawaguchi T , et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (12) 1190-1194
    CrossrefPubMedSuche in Google Scholar
  • 75 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132 (11) 1761-1766
    PubMedSuche in Google Scholar
  • 76 Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012; 11 (1) 18-27
    CrossrefPubMedSuche in Google Scholar
  • 77 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5) 1820-1832
    CrossrefPubMedSuche in Google Scholar
  • 78 Leung C, Yeoh SW, Patrick D , et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21 (4) 1189-1196
    CrossrefPubMedSuche in Google Scholar
  • 79 Schütte K, Schulz C, Poranzke J , et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 2014; 14: 117
    CrossrefPubMedSuche in Google Scholar
  • 80 Chagas AL, Kikuchi LO, Oliveira CP , et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz J Med Biol Res 2009; 42 (10) 958-962
    CrossrefPubMedSuche in Google Scholar
  • 81 Regimbeau JM, Colombat M, Mognol P , et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10 (2) (Suppl. 01) S69-S73
    PubMedSuche in Google Scholar
  • 82 Kojiro M. Pathology of early hepatocellular carcinoma: progression from early to advanced. Hepatogastroenterology 1998; 45 (Suppl. 03) 1203-1205
    PubMedSuche in Google Scholar
  • 83 Pawlik TM, Delman KA, Vauthey JN , et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11 (9) 1086-1092
    CrossrefPubMedSuche in Google Scholar
  • 84 Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31 (12) 1514-1521
    CrossrefPubMedSuche in Google Scholar
  • 85 Chen CI, Kuan CF, Fang YA , et al. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) 2015; 94 (6) e462
    CrossrefPubMedSuche in Google Scholar
  • 86 Chen HP, Shieh JJ, Chang CC , et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62 (4) 606-615
    CrossrefPubMedSuche in Google Scholar
  • 87 Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30 (5) 750-758
    CrossrefPubMedSuche in Google Scholar
  • 88 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330 (7503) 1304-1305
    CrossrefPubMedSuche in Google Scholar
  • 89 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9) 1766-1777
    CrossrefPubMedSuche in Google Scholar
  • 90 Hassan MM, Curley SA, Li D , et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116 (8) 1938-1946
    CrossrefPubMedSuche in Google Scholar
  • 91 Kawaguchi T, Taniguchi E, Morita Y , et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010; 30 (3) 479-486
    CrossrefPubMedSuche in Google Scholar
  • 92 Nkontchou G, Cosson E, Aout M , et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96 (8) 2601-2608
    CrossrefPubMedSuche in Google Scholar
  • 93 Bhat M, Chaiteerakij R, Harmsen WS , et al. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20 (42) 15750-15755
    CrossrefPubMedSuche in Google Scholar
  • 94 McCarroll ML, Armbruster S, Pohle-Krauza RJ , et al. Feasibility of a lifestyle intervention for overweight/obese endometrial and breast cancer survivors using an interactive mobile application. Gynecol Oncol 2015; 137 (3) 508-515
    CrossrefPubMedSuche in Google Scholar
  • 95 Eckard C, Cole R, Lockwood J , et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013; 6 (4) 249-259
    CrossrefPubMedSuche in Google Scholar
  • 96 Rodriguez B, Torres DM, Harrison SA. Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9 (12) 726-731
    CrossrefPubMedSuche in Google Scholar
  • 97 Piguet AC, Saran U, Simillion C , et al. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J Hepatol 2015; 62 (6) 1296-1303
    CrossrefPubMedSuche in Google Scholar
  • 98 Zhang X, Harmsen WS, Mettler TA , et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60 (6) 2008-2016
    CrossrefPubMedSuche in Google Scholar
  • 99 European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48 (5) 599-641
    CrossrefPubMedSuche in Google Scholar
  • 100 Sangiovanni A, Prati GM, Fasani P , et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43 (6) 1303-1310
    CrossrefPubMedSuche in Google Scholar
  • 101 Patterson AD, Maurhofer O, Beyoglu D , et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71 (21) 6590-6600
    CrossrefPubMedSuche in Google Scholar
  • 102 Kikuchi L, Oliveira CP, Alvares-da-Silva MR , et al. Hepatocellular carcinoma management in nonalcoholic fatty liver disease patients: applicability of the BCLC staging system. Am J Clin Oncol 2014; . Epub ahead of print
    PubMedSuche in Google Scholar
  • 103 Tateishi R, Okanoue T, Fujiwara N , et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol 2015; 50 (3) 350-360
    CrossrefPubMedSuche in Google Scholar
  • 104 Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg 2011; 15 (8) 1450-1458
    CrossrefPubMedSuche in Google Scholar
  • 105 Kurmann A, Wanner B, Martens F , et al. Hepatic steatosis is associated with surgical-site infection after hepatic and colorectal surgery. Surgery 2014; 156 (1) 109-116
    CrossrefPubMedSuche in Google Scholar
  • 106 Viganò L, Conci S, Cescon M , et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 2015; 63 (1) 93-101
    CrossrefPubMedSuche in Google Scholar
  • 107 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7 (7) 800-806
    CrossrefPubMedSuche in Google Scholar
  • 108 Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl 2009; 15 (Suppl. 02) S83-S89
    CrossrefPubMedSuche in Google Scholar
  • 109 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16 (4) 431-439
    CrossrefPubMedSuche in Google Scholar
  • 110 Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9 (4) 782-793
    CrossrefPubMedSuche in Google Scholar
  • 111 Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009; 15 (12) 1843-1851
    CrossrefPubMedSuche in Google Scholar
  • 112 Malik SM, Ahmad J. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2010; 16 (4) 533
    PubMedSuche in Google Scholar
  • 113 Liu YL, Patman GL, Leathart JB , et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61 (1) 75-81
    CrossrefPubMedSuche in Google Scholar
  • 114 Singal AG, Manjunath H, Yopp AC , et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 109 (3) 325-334
    CrossrefPubMedSuche in Google Scholar
  • 115 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10 (11) 656-665
    CrossrefPubMedSuche in Google Scholar
  • 116 Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci 2015; 16 (3) 5161-5179
    CrossrefPubMedSuche in Google Scholar
  • 117 Ratziu V, Bonyhay L, Di Martino V , et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35 (6) 1485-1493
    CrossrefPubMedSuche in Google Scholar
  • 118 Regimbeau JM, Abdalla EK, Vauthey JN , et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004; 85 (1) 36-41
    CrossrefPubMedSuche in Google Scholar
  • 119 Richani M, Kolly P, Knoepfli M , et al. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol . In press
    PubMed